Excellent - now I have comprehensive data from three authoritative sources. Let me compile the full answer.
Transfusion Reactions
Transfusion reactions are adverse events that occur as a consequence of blood component transfusion. They are broadly classified as immunologic or non-immunologic, and as acute (within 24 hours) or delayed (days to weeks after transfusion).
Classification Overview
| Category | Reaction | Timing |
|---|
| Immunologic - Acute | Acute hemolytic | During / <24 h |
| Febrile nonhemolytic (FNHTR) | During / <4 h |
| Allergic / Anaphylaxis | During |
| TRALI | Within 6 h |
| Hypotensive | During |
| Immunologic - Delayed | Delayed hemolytic | 2-21 days |
| Delayed serologic | Days-weeks |
| TA-GvHD | 1-6 weeks |
| Post-transfusion purpura | 5-10 days |
| Non-immunologic | TACO | During / <6 h |
| Septic/bacterial | During |
| Hypothermia, citrate toxicity, air embolism | During |
Incidence (per unit transfused - US data)
| Reaction | Risk |
|---|
| Febrile nonhemolytic | ~1 : 1,100 |
| Allergic | ~1 : 1,200 |
| Allergic (severe) | ~1 : 15,500 |
| TACO | ~1 : 9,000 |
| Delayed hemolytic | ~1 : 32,000 |
| TRALI | ~1 : 140,000 |
| Acute hemolytic | ~1 : 110,000 |
| TA-GvHD | <1 : 10,000,000 |
| Post-transfusion purpura | ~1 : 10,000,000 |
(Goldman-Cecil Medicine, Table 162-2)
1. Acute Hemolytic Transfusion Reaction (AHTR)
Mechanism: Preformed recipient antibodies (usually anti-A, anti-B IgM) bind transfused RBC antigens → antigen-antibody complex activates complement cascade → intravascular hemolysis. Most commonly caused by ABO incompatibility due to clerical/human error (wrong patient, wrong unit). As little as 10 mL of incompatible blood can trigger the reaction.
Cause: ~70% from RBC transfusions, ~30% from platelets. The most common cause is mistransfusion due to improper patient identification.
Symptoms:
- Fever, chills/rigors
- Chest pain, flank/back pain, abdominal pain
- Nausea, vomiting
- Dyspnea
- Hemoglobinuria (pink/red urine)
- Hypotension, shock
- Diffuse bleeding (DIC)
- Oliguria/anuria (acute renal failure)
Under general anesthesia: classic symptoms are masked. Hemoglobinuria, unexplained hypotension, or a bleeding diathesis may be the only clues. - Miller's Anesthesia, 10e
Labs:
- Decreased Hb, decreased haptoglobin
- Elevated LDH, elevated bilirubin
- Positive direct antiglobulin test (DAT)
- Hemoglobinuria (dipstick positive, NO RBCs on microscopy - distinguishes from hematuria)
- Incompatible crossmatch on repeat testing
- Prolonged PT/PTT, low fibrinogen (if DIC)
Treatment (Miller's Anesthesia protocol):
- Stop the transfusion immediately
- Maintain urine output ≥75-100 mL/h:
- IV fluids ± mannitol
- Furosemide if fluids/mannitol inadequate
- Alkalinize the urine (sodium bicarbonate)
- Assay urine and plasma hemoglobin
- Check platelets, PT, PTT, fibrinogen
- Return unused blood to blood bank for repeat crossmatch
- Send patient blood and urine to blood bank
- Prevent hypotension to ensure adequate renal blood flow
- Treat DIC with plasma, cryoprecipitate, platelets ± heparin
Complications: Acute renal failure, DIC. About 5% of ABO-incompatible transfusions are fatal; ~50% have no adverse effect.
2. Febrile Nonhemolytic Transfusion Reaction (FNHTR)
Most common type of transfusion reaction (~1:1,100).
Mechanism:
- Platelets: Leukocyte-derived cytokines (IL-1, IL-6, TNF) accumulate in the component during storage
- RBCs: Donor leukocytes interact with recipient white blood cell antibodies (anti-HLA, anti-granulocyte)
Definition: Temperature increase of ≥1°C (or >38°C) AND/OR chills/rigors within 4 hours of cessation of transfusion, with no other explanation.
Symptoms: Fever, chills, rigors. No hemolysis, no hypotension.
Diagnosis of exclusion - must rule out AHTR and septic reaction first.
Treatment:
- Stop transfusion, report to transfusion service
- Antipyretics (acetaminophen)
- Can restart with crossmatch-compatible blood once hemolytic reaction excluded
Prevention: Prestorage leukoreduction is the most effective measure (removes leukocytes before cytokine accumulation).
3. Allergic Transfusion Reaction
Second most common (~1:1,200). Range: mild urticaria to life-threatening anaphylaxis.
Mechanism: IgE-mediated allergic response to donor plasma proteins. Special case: IgA-deficient recipients (1 in 700 people) who have anti-IgA antibodies can develop severe anaphylaxis when exposed to IgA in donor plasma.
Symptoms:
- Mild: urticaria, hives, pruritus, flushing
- Severe (anaphylaxis): bronchospasm, laryngeal edema, hypotension, shock
Workup: No abnormal findings on standard transfusion reaction workup (no hemolysis).
Treatment:
| Severity | Management |
|---|
| Mild (localized urticaria) | Antihistamines; may restart transfusion after symptom resolution |
| Recurrent mild | Pretreat with antihistamines 30 min before transfusion |
| Severe/recurrent | Steroids 2-3 hours prior to future transfusions |
| Anaphylaxis | Parenteral epinephrine; stop transfusion permanently |
| IgA-deficient + anaphylaxis | Provide IgA-deficient donor units or washed cellular components |
4. Transfusion-Related Acute Lung Injury (TRALI)
Leading cause of transfusion-related mortality (FDA data 2012-2016).
Mechanism (two-hit model):
- Immune (antibody-mediated): Donor anti-HLA or anti-neutrophil antibodies bind recipient neutrophils → neutrophil activation → capillary leak in lungs
- Non-immune: Biologically active lipids from stored blood components prime/activate neutrophils in susceptible patients
Definition: New acute lung injury within 6 hours of transfusion, in the absence of pre-existing ALI, circulatory overload, or other ALI risk factors.
Symptoms: Acute dyspnea, hypoxemia (PaO₂/FiO₂ <300), bilateral pulmonary infiltrates on CXR - noncardiogenic pulmonary edema. No evidence of left heart failure (normal PCWP/CVP).
Treatment: Supportive - oxygen, mechanical ventilation if needed. No specific therapy. Do NOT give diuretics (unlike TACO).
Prevention: Use of male-only or never-pregnant plasma donors (female multiparous donors are the primary source of anti-HLA antibodies). Leukoreduction also helps.
5. Transfusion-Associated Circulatory Overload (TACO)
Mechanism: Simple volume overload from transfusion in patients with impaired cardiovascular reserve (elderly, renal failure, heart failure, pediatric patients).
Symptoms: Dyspnea, orthopnea, hypertension, tachycardia, pulmonary edema - cardiogenic pulmonary edema.
Distinguishing TRALI vs. TACO:
| Feature | TRALI | TACO |
|---|
| Mechanism | Non-cardiogenic | Cardiogenic |
| BP | Often hypotensive | Hypertensive |
| BNP | Normal/mildly elevated | Markedly elevated |
| Response to diuretics | No | Yes |
| CXR | Bilateral infiltrates | Bilateral infiltrates + cardiomegaly |
| PCWP | Normal | Elevated |
Treatment: Upright position, oxygen, diuretics (furosemide).
6. Delayed Hemolytic Transfusion Reaction (DHTR)
Timing: 2-21 days post-transfusion.
Mechanism: Patient was previously sensitized to RBC antigens (prior transfusion or pregnancy) but antibody level was too low to detect at pretransfusion screening. After transfusion, an anamnestic (secondary) immune response boosts the antibody titer → extravascular hemolysis in the reticuloendothelial system.
Antibodies involved: Predominantly Rh system (anti-D, anti-E, anti-C) and Kidd system (anti-Jk^a) - NOT ABO (unlike AHTR). More common in females.
Symptoms: Often subtle:
- Unexpected fall in hemoglobin 2-21 days post-transfusion
- Mild jaundice
- Positive DAT
- Rarely hemoglobinuria or renal impairment
- Rarely fatal
Clinical Pitfall: In postoperative patients, the unexplained Hb drop may be mistakenly attributed to surgical bleeding, leading to unnecessary return to the OR. - Miller's Anesthesia, 10e
Treatment: Usually self-limiting. Avoid future transfusion with the implicated antigen. Future crossmatch must use antibody-screened, antigen-negative blood.
7. Transfusion-Associated Graft-versus-Host Disease (TA-GvHD)
Mechanism: Viable donor T-lymphocytes engraft in an immunocompromised recipient, recognize host tissues as foreign, and mount an immune attack.
At-risk patients: Severe immunodeficiency, hematologic malignancies, allogeneic SCT recipients, neonates, congenital immunodeficiencies.
Symptoms: 1-6 weeks post-transfusion - fever, skin rash (erythroderma), diarrhea, hepatitis, bone marrow aplasia (pancytopenia).
Mortality: >90% - because unlike solid organ GvHD, the marrow is also attacked.
Prevention: Irradiation of cellular blood components (25 Gy) inactivates donor T-lymphocytes. Leukoreduction alone is NOT sufficient.
8. Post-Transfusion Purpura (PTP)
Timing: 5-10 days post-transfusion.
Mechanism: Recipient produces alloantibodies (typically anti-HPA-1a) against platelet antigens on donor platelets, which paradoxically also destroy the recipient's own platelets.
Symptoms: Sudden severe thrombocytopenia, purpura, mucosal bleeding.
Treatment: IV immunoglobulin (IVIg) is first-line; plasmapheresis for refractory cases.
9. Septic (Bacterial Contamination) Reaction
Mechanism: Transfusion of a bacterially contaminated blood component. Platelets (stored at room temperature) are at greatest risk.
Common organisms: Staphylococcus spp., Gram-negative bacteria in RBCs; Staphylococcus epidermidis, Staphylococcus aureus in platelets.
Symptoms: High fever, rigors, hypotension, shock - can mimic AHTR. Rapid deterioration.
Treatment: Stop transfusion; broad-spectrum antibiotics immediately; blood cultures from patient and bag; supportive care (vasopressors if needed).
Transfusion Reaction Workup
When a reaction is suspected, the following steps are standard (Quick Compendium of Clinical Pathology, 5th ed.):
- Stop transfusion immediately
- Clerical check: Verify patient ID on all paperwork and the blood bag - the most common cause of severe hemolytic reaction is clerical error
- Inspect serum/plasma for visible hemolysis (pink/red = hemolysis)
- Urine dipstick for hemoglobinuria (positive dipstick + no RBCs on microscopy = hemoglobinuria; distinguishes from hematuria)
- Repeat ABO typing on a post-transfusion sample
- Direct Antiglobulin Test (DAT): Positive DAT indicates antibody-coated RBCs. A negative DAT in AHTR can occur if hemolysis was complete and no transfused cells remain.
- Repeat crossmatch using pre- and post-transfusion samples
- Send blood from bag + patient sample to blood bank
- Transfusion service physician reviews workup; determines further testing
- Report to FDA within 7 days for fatalities or serious morbidity
Key Distinguishing Features at a Glance
| Feature | AHTR | FNHTR | Allergic | TRALI | TACO | DHTR |
|---|
| Timing | Immediate | <4 h | Immediate | <6 h | <6 h | 2-21 days |
| Fever | Yes | Yes | No | Yes | No | Mild |
| Hemolysis | Yes (intravascular) | No | No | No | No | Yes (extravascular) |
| Hypotension | Yes | No | Severe only | Yes | No | Rarely |
| Respiratory | No | No | Wheeze (severe) | Severe (ARDS) | Pulm edema | No |
| Urticaria | No | No | Yes | No | No | No |
| DAT | Positive | Negative | Negative | Negative | Negative | Positive |
| Antibody system | ABO | Anti-HLA/WBC | IgE vs plasma | Anti-HLA/neutrophil | N/A | Rh, Kidd |
| Key treatment | Stop; hydration; diuresis | Antipyretics | Epi (severe) | Supportive | Diuretics | Antigen-neg blood |
Sources: Goldman-Cecil Medicine International Edition (Ch. 162, pp. 1845-1848); Miller's Anesthesia 10e (Ch. 45, pp. 6653-6661); Quick Compendium of Clinical Pathology 5th ed. (§2.8.2, pp. 89-90)